← Back to blog

Noopept vs Piracetam: What the Human Trials Show

November 21, 2026
Noopept vs Piracetam: What the Human Trials Show

Noopept and piracetam are related compounds, and the only direct human comparison between them is a small Russian trial in patients with mild cognitive disorders, not in healthy people. In that trial the two performed similarly on standard cognitive tests, while noopept was given at a dose roughly 60 times smaller. Beyond that trial, the evidence for both is thin, and neither is approved by the FDA as a dietary ingredient. Below is what each compound is, how the studies compare, what the doses and side effects were, and how to read the evidence.

Nutrasmarts
Put Supplement Evidence in Context
Explore ingredient research and citations to assess what clinical evidence does, and does not, show about supplements.
Visit

TL;DR

  • Noopept was designed as a dipeptide analog of piracetam and is taken at far lower doses: 20 mg a day in the head-to-head trial versus 1,200 mg of piracetam.
  • In a 2009 randomized trial of 53 patients, no significant differences appeared between the two drugs on the MMSE, BPRS or CCSE scales.
  • Both studies' patients had vascular or traumatic brain disease. Evidence in healthy adults is limited for piracetam and essentially absent for noopept.
  • In the US, the FDA treats both as unapproved drugs, not dietary supplements.

Table of Contents

What noopept and piracetam are

Piracetam is the original "racetam." Its chemical name is 2-(2-oxopyrrolidin-1-yl)acetamide. It was first marketed by UCB Pharma in Belgium in 1971, and according to the Alzheimer's Association's Cognitive Vitality summary it is approved in some countries but not for any medical use in the US.

Noopept (also called omberacetam or GVS-111) was developed at the Zakusov Institute of Pharmacology in Russia. The same group's summary says it was built on piracetam's structure, with the stated advantage of a lower dose. Its full name is N-phenylacetyl-L-prolylglycine ethyl ester. Both molecules share a pyrrolidine ring, an amide group and a glycine fragment, which is why noopept is often described as a piracetam relative rather than a copy.

You can read each ingredient's profile, dosage ranges and citations on our pages for piracetam and noopept.

How they are thought to work differently

The mechanisms are not settled, but laboratory work points to a real difference. A peer-reviewed molecular study from Russian researchers (Vakhitova et al., 2016) tested both compounds on a panel of transcription factors, which are proteins that switch genes on and off. Noopept at 10 μM selectively increased the activity of HIF-1, while piracetam at 1 mM did not significantly affect any of the factors tested. The authors propose that noopept acts mainly through inhibiting an enzyme called prolyl hydroxylase 2. The same paper reports that noopept's activity resembles piracetam's but appears at doses 1,000 times lower, with more pronounced anxiolytic and neuroprotective properties in animal models. It also describes increased NGF and BDNF expression in the hippocampus, two proteins involved in the growth and survival of neurons.

Another detail matters for how people read dosing claims. Noopept itself is cleared very quickly: the Alzheimer's Association summary reports a half-life of about 5 to 10 minutes in rodents and no detectable noopept in the brain after an hour. A metabolite, cycloprolylglycine, is elevated at one hour and is thought to carry the longer-term effects. Piracetam, by contrast, has a half-life of about 5 hours in young adult men.

These are cell and animal findings. They explain why researchers study the two compounds separately, not how either will feel or perform in a person.

The head-to-head human trial

Only one randomized comparison is widely cited. Neznamov and Teleshova published it in 2008 and 2009. The 2009 paper covers 53 patients with mild cognitive disorders from organic brain disease of vascular or traumatic origin. Treatment ran 56 days.

NoopeptPiracetam
Dose in the trial20 mg/day, two doses1,200 mg/day, three doses
Duration56 days56 days
PatientsVascular and post-traumatic cognitive disordersSame groups
Cognitive scales (MMSE, BPRS, CCSE)No significant difference from piracetamNo significant difference from noopept

Within the vascular group, noopept produced marked improvement in 47.6% of patients and significant improvement in 42.9%, with no improvement in 9.5%. The authors described piracetam's antiasthenic (anti-fatigue) and anxiolytic effects as less marked. Most post-concussion patients on piracetam stopped early because of side effects or lack of effect.

The Alzheimer's Association summary cites this as the only peer-reviewed human trial of noopept it found. In the noopept group, the MMSE (a 30-point screening test of orientation, memory and attention) rose from 26 to 29. The summary's overall conclusion is that little clinical evidence supports noopept's use.

The head-to-head human trial

What the trial can and cannot tell you

The participants were patients with diagnosed brain disease, in a single country, on a 56-day course. That is a useful signal for researchers and clinicians. It does not show how either compound performs in a healthy student or professional, and nobody should read an MMSE gain of three points in patients as a prediction for a healthy brain. The trial also shows that a comparison on test scores can come out as a tie while the side-effect experience differs.

What piracetam's larger evidence base looks like

Piracetam has far more studies, and they point in different directions depending on how outcomes are measured.

  • A 2002 meta-analysis of 19 double-blind trials covering 1,489 older adults with cognitive impairment reported that 63.9% improved on piracetam versus 34.1% on placebo on clinical assessment.
  • A Cochrane review of 24 trials and 11,959 participants found a pooled odds ratio of 3.43 for improvement in global impression of change, but no significant differences on specific measures such as immediate memory, delayed memory, MMSE or speech. The authors concluded the published evidence does not support its use in dementia or cognitive impairment, and noted that only one study ran longer than six months and that unpublished data raise the possibility of publication bias.
  • For healthy adults, the Alzheimer's Association says studies of piracetam's true cognitive effects are limited.

A 2001 crossover trial in children with Down syndrome (Lobaugh et al.) adds a useful caution about interpretation. Piracetam did not improve cognitive performance over placebo, and the authors suggested that the perceived benefits in popular accounts may reflect stimulation, meaning alertness that feels like focus, rather than measured gains.

The practical lesson for either compound: ask which outcome was measured, in which population, for how long.

Doses in the research

Doses differ by orders of magnitude, which is the main reason people say noopept is "stronger." That wording hides a point. A lower milligram dose reflects a different molecule, not a proven larger effect.

CompoundDoses reported in the sourcesSetting
Noopept20 mg/day in two doses (2009 trial); 10 mg twice daily in the Alzheimer's Association summary of the same 56-day studyPatients with mild cognitive disorders
Piracetam1,200 mg/day in three doses (2009 trial)Same trial
Piracetam2.4 to 9 g/dayStudies in cognitive impairment and dementia
Piracetam1,200 to 4,800 mg/day in adults per the Alzheimer's Association summary; most trials used 4.8 g/dayClinical research

A 2022 review of nootropics adds that piracetam's intravenous acute dose is 4 to 8 g/day, with a maintenance dose of about 2 to 4 g/day adjusted for kidney function. The same review notes that efficacy depends on dose and that nootropics are contraindicated in hypersensitivity, pregnancy and lactation.

Because piracetam is cleared by the kidneys, anyone with suspected kidney or bleeding problems should speak with a doctor before taking it, as the Alzheimer's Association summary advises.

Side effects and interactions

Safety data is limited for both, so these figures are the ones that exist.

Noopept. In the open-label trial the Alzheimer's Association summarizes, sleep disturbances occurred in 5 of 31 patients, irritability in 3 of 31 and raised blood pressure in 7 of 31. Drug interactions are not known, because noopept is an unapproved nootropic with little clinical use. If you take blood pressure medication or have a history of high blood pressure, talk with your doctor first.

Reported noopept trial side-effect counts

Piracetam. The Alzheimer's Association summary lists interactions with anticoagulants, aspirin and thyroid extracts, and says it may worsen neuropsychiatric symptoms in frontotemporal dementia. The 2022 review lists rare side effects including insomnia, irritability, increased libido and changes in sexual function. In the Down syndrome trial above, 7 of 18 children who completed the study had stimulatory effects such as aggressiveness or agitation, which is why children should only receive it under a physician's care.

If you are pregnant, nursing, on a blood thinner, or managing a kidney or thyroid condition, your prescriber or pharmacist is the right person to ask before you take any compound from this family.

In the United States, neither compound is an FDA-approved drug, and neither qualifies as a dietary ingredient. The FDA has said so directly in warning letters. A February 2019 letter to a nootropics retailer states that noopept, piracetam and several other racetams are not dietary supplements or conventional foods and do not qualify for the exception from the definition of a drug. The Alzheimer's Association summary likewise notes piracetam is not permitted to be sold as a dietary supplement in the US.

For formulators, this matters on the label: neither belongs in a Supplement Facts panel. Rules and enforcement priorities can change, so check the FDA's warning-letter database for the latest before you plan a product.

How to choose: three questions to ask

  1. Who was studied? Patients with vascular or traumatic brain disease, older adults with impairment, children, or healthy adults. Match the study to your situation, or acknowledge the gap.
  2. What was measured? A global impression of change and an objective memory test can disagree, as the piracetam reviews show.
  3. How long, and how many? The key noopept comparison ran 56 days in 53 people. That is a starting point for further research, not a settled answer.

If your goal is focus or memory and you want ingredients with human trials that are legal to sell as supplements in the US, our pages on citicoline, bacopa, phosphatidylserine and ginkgo lay out the clinical evidence and typical doses. For an everyday routine, a nootropic coffee comparison shows how focus-oriented blends with adaptogens differ.

Other racetams have their own profiles if you are reading across the family: aniracetam, oxiracetam, phenylpiracetam and pramiracetam.

Compare ingredients side by side

NutraSmarts is free to use, with no sign-up or paywall. Each ingredient profile ties its claims to PubMed-cited studies and clinical dosage benchmarks, and our side-by-side comparison guides put two ingredients next to each other on dose, mechanism and evidence rating, the way this article does for noopept and piracetam. You can also search by symptom, such as brain fog, to see which ingredients have clinical support for it.

Nutrasmarts

Start with the supplements by symptom search, browse the full ingredient database, or open the side-by-side comparison guides. If you formulate products, the free Supplement Facts label creator builds an FDA-compliant panel in your browser, with no spreadsheets.

Our perspective

We built NutraSmarts because ingredient pages too often blur the line between a lab result, a small patient trial and a proven benefit. Noopept and piracetam show why that line matters.

A cell study showing that noopept switches on HIF-1 and piracetam does not is interesting science. A 53-patient trial showing a tie on cognitive scales is a real human data point. Neither tells a healthy adult what to expect. We rate evidence honestly and put the population, dose and duration next to each claim, so you can judge for yourself.

Our ingredient profiles link to PubMed-cited studies and clinical dosage benchmarks, and our comparison tool lets you put two ingredients side by side before you decide. Researchers and coaches get the citations. Consumers get a plain reading of what those citations show.

NutraSmarts

FAQ

Is noopept stronger than piracetam?

Noopept is active at much lower doses, 20 mg a day versus 1,200 mg in the 2009 trial. But in that trial the two did not differ significantly on cognitive scales. A smaller dose reflects a different molecule, not a proven bigger effect.

Can I take noopept and piracetam together?

No study in the sources we reviewed tested the combination, and noopept's drug interactions are unknown. Piracetam is known to interact with anticoagulants, aspirin and thyroid extracts. Ask your doctor or pharmacist before combining any compound with your medicines.

They are not approved as drugs, and the FDA has stated in warning letters that they are not dietary supplements. That makes them unsuitable for a US supplement label. Check the FDA's site for current enforcement information.

Do they improve memory in healthy people?

The evidence is limited. The Alzheimer's Association says studies of piracetam in healthy adults are limited, and its noopept summary says little clinical evidence supports use. The trials that exist enrolled patients with cognitive impairment.

Sources